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SCIENTIFIC EDITORIAL
Cryoablation for curing reciprocating tachycardia: 
take the good and leave the bad
Cryoablation pour le traitement des tachycardies réciproques : 
essayons d’en garder surtout les avantages
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Département de cardiologie, Groupe hospitalier Lariboisière (AP-HP), Paris.
The introduction into clinical practice, approximately
25 years ago, of catheter ablation for cardiac arrhythmias
has dramatically changed our understanding of and treat-
ment approach for arrhythmias [1]. The concept of cathe-
ter-based destruction of the arrhythmogenic substrate ins-
tead of simply trying to modify it using antiarrhythmic drugs
has transformed a preventive palliative approach into a
definitive curative treatment, thus explaining the dramatic
and widespread rise in use of this technique.
The type of energy used to damage the myocardial tissue
has been critical from the early days. The first – direct-cur-
rent delivery – was associated with a high risk of acute com-
plications and a low spatial accuracy [2]. These problems
have been largely overcome by the use of Radiofrequency-
energy [3]. Radiofrequency-induced resistive heating leads
to lesion formation in the myocardial tissue. It is characteri-
zed by much better spatial resolution together with impro-
ved control of energy delivery compared with direct-current
energy. As a consequence, the development of catheter
ablation is closely related to the use of appropriated
radiofrequency catheters in the electrophysiology (EP) lab.
Important improvement in energy titration by power, tem-
perature, and impedance control has been obtained, thus
minimizing the risk of complications related to energy deli-
very [4] without hampering efficacy. Nevertheless, the ina-
bility to assess the electrophysiological effect of radiofre-
quency energy before it becomes irreversible represents its
main drawback. Radiofrequency ablation is associated with
a risk of damaging the physiological conduction pathway(s)
between the atria and the ventricles, leading to potentially
irreversible complete atrioventricular (AV) block when abla-
tion is performed on parts or in the vicinity of the compact
AV node. This was in fact the goal of initial procedures per-
formed in the eighties [2, 3]. Although this risk has been
minimized by improvement in target definition [5], it is still
a potential complication when ablating or modulating the
slow pathway for the cure of AV nodal re-entrant tachycar-
dia (AVNRT). This complication leads to pacemaker implan-
tation in approximately 1% of AVNRT-radiofrequency abla-
tions [6]. The risk of AV block is also present during
radiofrequency RF ablation of mid-septal accessory
pathways [7]. Although uncommon, implantation of a pace-
maker is a devastating complication in young healthy sub-
jects, and this complication is difficult to accept for the
treatment of benign arrhythmias such as AVNRT.
Cryothermal energy – long used during open chest cardiac
surgery – has the main advantage of assessing the electro-
physiological effect of energy delivery before definite
lesion formation [8, 9]. As a consequence, one can “cryo-
map” (at -30°C) any targeted spot to create reversible
electrophysiological effects and then perform a full cryoa-
blation (at -80°C) in safe regions, thus avoiding the risk of
AV block. Others features of cryoablation, such as preserva-
tion of tissue architecture, may be used to prevent vein ste-
nosis and/or cardiac perforation during left atria ablation
[10]. 
Development of cryocatheter ablation first took place in
the setting of slow pathways and mid-septal accessory
pathways. The advantage of cryothermal energy for mid-
septal accessory pathway ablation is clear since such a loca-
tion would have represented a contraindication to radiofre-
quency ablation, with the exception of life-threatening
Wolff-Parkinson-White syndrome. The advantage of cryo-
energy for curing AVNRT is less obvious. Acute slow-
pathway ablation or modulation using a cryocatheter has
been shown to be almost as efficient as that with radio-
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frequency [11, 12]. However, cryo catheters have a relati-
vely poor maneuverability, the energy application times
and hence the procedure times are longer than with
radiofrequency catheter, the electrophysiological criteria
to define the target and ablation efficacy are sometimes
difficult to obtain, and cryocatheters are more expensive.
Nonetheless, the main concern with cryoablation of the
slow pathway is the high proportion of recurrences, rea-
ching 20% in some reports [13, 14]. 
The decision to use a cryocatheter instead of a conven-
tional radiofrequency catheter should involve thorough
assessment of the advantages and disadvantages. On the
one hand, ablating the slow pathways by cryo will improve
the security of the procedure but at the cost of loss of effi-
ciency, thus increasing the need for procedures with their
associated potential complications. This “safe” approach
can be easily explained to the patients and their referring
cardiologist before the procedure, but explaining the need
for a repeat procedure would be more gruesome in case of
early recurrence… In addition, in some cases it is not possi-
ble to ablate with a cryocatheter, and it would then be dif-
ficult to switch to a conventional radiofrequency catheter
when the patient has been told that the risk for AV block
would be negligible. On the other hand, using only radiofre-
quency energy could be considered as taking an unjustified
and/or unacceptable risk of AV block. The question is still
the matter of debate, and some centers have decided to
ablate all AVNRTs by cryo while others continue to use
radiofrequency energy.
In the present issue of Archives of CardioVascular
Diseases, Nadji et al. describe the pragmatic approach they
use in Amiens University hospital [13]. In this non-randomi-
zed, real-life study, the authors compared the efficacy and
complication rates of the two approaches – radiofrequency
and cryo – when ablating AV nodal or AV-reciprocating
tachycardia in 199 patients. The decision to use cryo energy
instead of radiofrequency was based on predefined electro-
physiological criteria of augmented risk of AV block, inclu-
ding transient AV block during previous radiofrequency
application, a small Koch triangle with a narrow safety mar-
gin, mid-septal and para-Hisian accessory pathways, and
clinical criteria such as patient age below 25 years or
because of the referring physician’s request. Applying these
criteria, cryo energy was used in 13% of patients (9% of
those with an AVRT and 16% with an AVNRT). 
Using this strategy, no permanent AV block was observed
among the overall population of the study, thus suggesting
the safety of such an approach. The only potential problem
with the Amiens strategy is represented by the non-predic-
table AV blocks, i.e. those that develop despite ablating far
from spots considered to be “dangerous”. Otherwise, this
strategy is flexible, allowing the operator to switch
between the two energies when needed. In the study by
Nadji et al., 8 of 26 patients received cryo applications
after radiofrequency and 4 of 26 radiofrequency after cryo
applications, thus improving the acute success rates
without complications. The recurrence rate with cryo was
50% for mid-septal and para-Hisian accessory pathway abla-
tion, but it is important to keep in mind that such accessory
pathways would probably not have been targeted with
radiofrequency energy [7]. In line with a previous study [12,
14], Nadji et al. report a 22% recurrence rate after AVNRT
cryoablation. But since cryo energy was used in only 16% of
AVNRT ablations, the overall recurrence rate in their
AVNRT ablation series was only 4%. 
The strategy proposed by Nadji et al. appears safe, with
an acceptable overall recurrence rate, and is cost effec-
tive. This smart approach is a first step to future studies
aiming to validate better-defined patient-specific criteria
for a rational choice of energy with which to perform the
ablation. However, it is already clear that the two energies
are complementary tools that should both be available in
the EP lab to help the electrophysiologist ablate previously
untouchable accessory pathways and to minimize the risk of
complications without hampering the success rates for
AVNRT ablation.
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